Across the world, patients who once may have had little hope of survival are benefiting from the treatment efficacy and potentially curative potential of novel cell therapies, advancing industry growth in this innovative and highly specialist area. These powerful ‘living drugs’ are by their very nature complex to produce and the manufacturing expertise required cannot be underestimated. While some general principles can be applied to the development of cell therapy treatments, it is important to consider, says Rachel Griffiths at PCI, that each product presents its own specific challenges and complexities for managing its generation, manufacture and delivery to the patient.

[wonderplugin_pdf src=”https://www.biopharmaceuticalmedia.com/wp-content/uploads/2018/12/The-cell-therapy-supply-chain-and-risk.pdf” width=”100%” height=”900px” style=”border:0;”]